Tresiba® (insulin degludec) and Ryzodeg® (insulin degludec/insulin aspart) receive positive opinions from the European regulatory authorities
2012-10-19 · Novo Nordisk A/S · original novonordisk.com ↗
Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) adopted positive opinions, recommending marketing authorisations, for Tresiba® and Ryzodeg® for the treatment of diabetes mellitus in adults. Further information: Media: Investors: Mike Rulis Kasper Roseeuw Poulsen Tel: (+45) 3079 3573 Tel: (+45) 4442 4303 [email protected] [email protected] Frank Daniel Mersebach Tel: (+45) 4442 0604 [email protected] Lars Borup Jacobsen Tel: (+45) 3075 3479 [email protected] In North America: Ambre Morley Jannick Lindegaard Tel: (+1) 609 216 5240 Tel: (+1) 609 786 4575 [email protected] [email protected] Company announcement No 66 / 2012
The release as fetched from its publisher. novonordisk.com ↗